Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the ...

Callander, MD, discussed the rationale for a quadruplet regimen being evaluated in patients with relapsed/refractory multiple ...

Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with ...

Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.

A clinical trial of adjuvant intismeran (V940) with or without pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) in high-risk stage I non-small cell lung cancer (V940-014) ...

Emory University Hospital was recently selected as the first medical center to adopt the Liberty endovascular robotic system, developed by Microbot Medical and granted 510(k) clea ...

A growing number of anticancer therapies once available only as intravenous (IV) infusions now have subcutaneous formulations. These can shorten chair time for patients and change how infusion centers ...

A clinical trial of adjuvant intismeran (V940) with or without pembrolizumab coformulated with berahyaluronidase alfa ...

Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer. In an interview with ...

Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.

Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across ...

Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer. To better understand the potential clinical implications of ...